<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681145</url>
  </required_header>
  <id_info>
    <org_study_id>HD51-SF-060</org_study_id>
    <nct_id>NCT03681145</nct_id>
  </id_info>
  <brief_title>Youth to Text or Telehealth for Engagement in HIV Care</brief_title>
  <acronym>Y2TEC</acronym>
  <official_title>Youth to Text or Telehealth for Engagement in HIV Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California HIV/AIDS Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Youth To Text or Telehealth for Engagement in HIV Care (Y2TEC) is a randomized control pilot
      to assess the feasibility and acceptability of delivering a targeted problem-solving
      intervention to youth ages 18-29 living with HIV (YLWH) for improving HIV care engagement,
      mental health, and decreasing substance use. The intervention will be delivered to
      participants in two condition groups in remote telehealth sessions delivered via
      video-conference over 4 months. Participation in the study will last about 8 months.

      The investigators hypothesize that the Y2TEC intervention will be feasible and acceptable for
      YLWH, and will result in improved HIV clinical outcomes. If feasible and acceptable, it can
      be scaled up for a multi-site randomized clinical trial and ultimately offered in the
      clinical care of YLWH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Due to a 50% increase in HIV-related deaths in youth from 2005 to 2012, there is a critical
      need for research to address health disparities in youth ages 18 to 29 years old living with
      HIV (YLWH) and for the tailoring of healthcare delivery to their unique and complex health
      needs. YLWH experience worse clinical outcomes than adults including high rates of mental
      health and substance use challenges that impact their medical care and adherence. Many YLWH
      have sub-optimal engagement in HIV care, including missed HIV provider visits and routine lab
      work. The consequence of suboptimal adherence in YLWH is increased risk of HIV transmission
      and a future generation of immunodeficient adults with drug-resistant virus. In response to
      this critical public health dilemma, the researchers propose to develop a telehealth
      intervention for YLWH focused on addressing engagement in HIV care, mental health, and
      substance use challenges. Telehealth holds promise in overcoming barriers to clinic
      attendance or research participation, such as transportation difficulties or HIV-related
      stigma concerns. Text messaging has also been used successfully for Antiretroviral therapy
      (ART) adherence and virologic suppression in African settings and has been examined in youth.
      The investigators have chosen these technology-based methods due to the presence of data
      supporting their efficacy, feasibility and acceptability, promise for future dissemination,
      limited research in YLWH, and ability to tailor based on patients' unique health needs. While
      these technologies can act on specific barriers to engagement in HIV care, they are inversely
      related in cost, burden to patient and provider, and intensity. Existing interventions for
      YLWH have been adapted to create the Youth to Text or Telehealth for Engagement in HIV Care
      Intervention (Y2TEC) through text messaging and teleconferencing (telehealth).

      The Y2TEC telehealth intervention uses problem-solving therapy, a strengths-based
      orientation, and motivational interviewing to help participants identify and resolve
      potential barriers to engagement in HIV care and other barriers to overall wellness.
      Consisting of twelve 20-30 minute sessions with a trained social worker using a menu of
      structured sessions. Each session will focus on a specific topic as it relates to healthcare
      engagement and wellness, such as substance use, family support, or social support. The
      curriculum is designed increase engagement in HIV care and reduce viral loads. To achieve
      these outcomes, the behaviors most commonly targeted through the problem-solving activities
      will be related to medication adherence, attending clinic visits, and completing labs.

      At the end of the study, the investigators will explore feasibility and acceptability using
      quantitative and qualitative methods. Participants will complete quantitative surveys at
      baseline, 4 months, 8 months, and study completion, as well as qualitative exit interviews
      conducted over the phone. Participants will consent to the study in person and will be
      randomized into one of two condition groups to receive the following: Group A: participants
      will immediately receive 1 brief counseling intervention in-person and 11 subsequent weekly
      sessions delivered remotely via video-conference and weekly text messaging. Then cross over
      to a waiting period receiving text messages for 12 weeks. Group B: Participants in the
      wait-list after consent and receive text messaging only for a period of 12 weeks then will
      receive a revised version of the intervention for 12 weeks with all sessions completed
      remotely via video-conference and text message.

      The aims of this study are:

        1. Employ: (1) mixed methods research to assess engagement in HIV care, technology use,
           substance use, and challenges with current systems of care among YLWH (18-29 years), (2)
           qualitative research to examine the perceptions of clinicians/managers of clinics and
           organizations serving YLWH on available referral services, system-wide barriers to care
           or referrals to substance use treatment, and age-specific challenges to patient care.

        2. Develop a technology-based intervention for improving mental health and reducing
           substance for delivery in YLWH based on prior data and information learned in Aim 1.

        3. Examine feasibility, acceptability, and preliminary clinical outcomes of the
           technology-based intervention among YLWH on improved engagement in HIV care and mental
           health, and reduced substance use.

      The investigators hypothesize that the Y2TEC intervention will be feasible and acceptable for
      YLWH. Our secondary hypotheses: H1: Antiretroviral adherence, engagement in care, and CD4+
      cell count will be higher and HIV RNA levels will be lower in the intervention arm (Group A)
      relative to the wait-list arm (Group B) at 4 months. H2: Among those enrolling in the study
      with a detectable HIV RNA, there will be a minimum of 1log10 reduction in HIV RNA at 4 months
      among the intervention arm and at 8 months among the wait-list arm relative to baseline and 4
      months, respectively. H3: Among those enrolling in the study with an undetectable HIV RNA,
      there will be a maintenance of virologic suppression at 4 months among the intervention arm
      and at 8 months among the wait-list control arm relative to baseline and 4 months,
      respectively.

      The investigators postulate parallel hypotheses for self-reported ART adherence, appointment
      attendance based on medical records, and self-reported composite of engagement in care with
      mean levels of these variables being highest in the Telehealth arm and lowest in the control
      arm. Conversely, the screener for substance use (CRAFFT score) should be highest in the
      control arm and lowest in the Telehealth arm. If this innovative intervention is found to be
      feasible and acceptable, it can be scaled up for a multi-site adaptive randomized trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility: Participant Retention at 4 months</measure>
    <time_frame>4 months</time_frame>
    <description>Percentage of participants retained in the study at 4 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Mean Number of Teleconference Disconnections</measure>
    <time_frame>8 months</time_frame>
    <description>Mean of one disconnection per videoconferencing session</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Video Quality</measure>
    <time_frame>4 months</time_frame>
    <description>1 item, Likert scale (0-10) (0= poor quality; 10= excellent quality) To calculate feasibility by video quality, the investigators will report the average score among all users.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Sound Quality</measure>
    <time_frame>4 months</time_frame>
    <description>1 item, Likert scale (0-10) (0= poor quality; 10= excellent quality) To calculate feasibility by sound quality, the investigators will report the average score among all users.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Participant Response Time to Text</measure>
    <time_frame>8 months</time_frame>
    <description>Mean number of days between bi-directional text message and participants' response</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability: Measure participant satisfaction of the telehealth intervention as assessed by use of original 30-item satisfaction survey</measure>
    <time_frame>8 months</time_frame>
    <description>Measure participant satisfaction with the telehealth intervention at 8-months using a 30-item questionnaire (1 Excellent-6 Unsatisfied) administered through an online survey. An average score greater than or equal to 144 (80%) will be considered acceptable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability: Measure participant satisfaction of the telehealth sessions from 0 to 8 months via 2-item scale adapted from Session Rating Scale (SRS)</measure>
    <time_frame>8 months</time_frame>
    <description>Measure participant satisfaction of each telehealth session via 2-item scale adapted from Session Rating Scale (SRS) (1-Strongly Agree to 4 Strongly Disagree, lower rating indicates higher satisfaction) administered by text-messaging. Average participant satisfaction over 12 telehealth sessions from baseline to 8 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Participant Retention at 8 months</measure>
    <time_frame>8 months</time_frame>
    <description>Percentage of participants retained in the study at 8 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Impact: Self-reported medication adherence</measure>
    <time_frame>8 months</time_frame>
    <description>Measure changes in participants' self-reported medication adherence based on 1-item adherence rating (1-Excellent- 6 Poor, lower rating indicates higher adherence) from baseline to 8 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Impact: Frequency of Substance Use</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Measure participants' change in substance use from baseline to 8 months using a 10-item questionnaire adapted from the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) administered through an online survey to measure frequency of participants' substance use. Scoring range is 0-Never to 6 almost daily, lower rating indicates lower substance use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Substance Use from 0 to 8 months</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Measure participants' changes in substance use from baseline to 8 months using the Drug Abuse Screening Test (DAST), a 10-item questionnaire administered through an online survey to measure severity of participants' substance use. Responses are summed. Scoring (0-10);0-2 Low substance use, 9-10 Severe substance use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alcohol Use</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Measure participants' alcohol use from baseline to 8 months using the Alcohol Use Disorder Test (AUDIT), a 10-item questionnaire administered through an online survey to measure severity of participants' alcohol use. Responses are summed. Scoring range is 0-20+; 0-7 Low alcohol use, 20+ High dependence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Impact: Depression</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Measure participants' depression from baseline to 8 months using the Patient Health Questionnaire ( PHQ-9), a 9-item Likert scale score (0 - 3) 0 &quot;not at all&quot;, 3 &quot;nearly every day&quot;. Responses are summed. Scores will have a range of 0-27. PHQ-9 scores of &gt; 10 are associated with moderate to severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Impact: Post Traumatic Stress Disorder (PTSD)</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Measure participants' self-reported PTSD from baseline to 8 months using the Psychopathy Checklistâ€”revised (PCL), a 20-item Likert questionnaire administered through an online survey. Scoring: 0 points for &quot;not at all&quot;, 1 point for &quot;a little bit&quot;, 2 points for &quot;moderately&quot;, 3 points for &quot;quite a bit&quot;, 4 points for &quot;extremely&quot;.Scores will have a range of 0-80. Responses are summed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure participant HIV Knowledge using HIV Treatment Knowledge Scale</measure>
    <time_frame>0 to 8 months</time_frame>
    <description>Assess participants' knowledge of HIV from baseline to 8 months through the HIV Treatment Knowledge measure, a 15-item self-report questionnaire. Scoring out of 15 (0-11 Inadequate, 12-15 Adequate). Scores will have a range of 0-15.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>HIV/AIDS</condition>
  <condition>Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse)</condition>
  <condition>Depression</condition>
  <condition>Substance Use</condition>
  <arm_group>
    <arm_group_label>Group A-Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the study intervention immediately after study enrollment has been completed. The intervention will be delivered in 12, 20-30 minute sessions and text messaging over 4 months (1st session in person, remaining 11 sessions will be remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B-Wait-list</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be placed in a waitlist group for four months after study enrollment. Participants will receive the revised study intervention in 12, 20-30 minute sessions and text messaging over 4 months( all sessions remote). The investigators will asses feasibility, acceptability and preliminary clinical outcomes of the Y2TEC intervention at 4 months and 6 months. During the waiting period, participants will receive text messages.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Counselor delivered telehealth intervention</intervention_name>
    <description>This is a technology-based counseling intervention for youth living with HIV (YLWH) focused on engagement in HIV care, mental health, and substance use challenges through text messaging and teleconferencing (telehealth). The intervention is delivered in 12 brief sessions.</description>
    <arm_group_label>Group A-Intervention</arm_group_label>
    <arm_group_label>Group B-Wait-list</arm_group_label>
    <other_name>Y2TEC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English-speaking

          -  HIV+

          -  Youth (18-29 years)

          -  Living or receiving health care in the eastern region of the San Francisco Bay Area
             (i.e.

        East Bay)

          -  Willing and able to provide informed consent

          -  Access to a mobile phone with text messaging capability

          -  Access to the internet through a mobile phone, computer or tablet

        Exclusion Criteria:

        The Investigators will exclude those with evidence of severe cognitive impairment or active
        psychosis that may impede the ability to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parya Saberi, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF School of Medicine, Division of Prevention Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco Mission Hall</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Young Adults</keyword>
  <keyword>Telehealth</keyword>
  <keyword>Health Disparity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

